Mardi Dier - 14 Oct 2022 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Reporting relationship: CFO & Executive Vice President
Issuer ticker: RARE
Reported as of: 14 Oct 2022
Net transaction value: -$65,421
SEC form: 4
Accepted by SEC: 17 Oct 2022, 18:49:56 UTC
Prior SEC filing: 14 Oct 2022
Next SEC filing: 04 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Karah Parschauer, attorney-in-fact

Key filing fact

Mardi Dier filed Form 4 for Ultragenyx Pharmaceutical Inc. (RARE) on 17 Oct 2022.

Key facts

This page summarizes Mardi Dier's Form 4 filing for Ultragenyx Pharmaceutical Inc. (RARE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 17 Oct 2022, 18:49.

Change

Previous filing in this sequence was filed on 14 Oct 2022.
Current net transaction value: -$65,421.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RARE transaction

Common Stock

Sale

Transaction value: $65,421
Shares: -1,629
Change %: -2.4%
Price: $40.16
Shares after: 66,695
Date: 14 Oct 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Footnote F2

Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.